Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without G-CSF in high-risk myelodysplastic syndrome and related myeloid neoplasms
2013-001639-38Phase 4Completed
- Sponsor
- 1st Department of Medicine, General University Hospital in Prague
- Start
- Jul 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of azacitidine and filgrastim in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by 1st Department of Medicine, General University Hospital in Prague. Primary endpoints: Overall survival prolongation, Delay of transformation to acute leukemia and 4 more. Started Jul 2016; status: completed.
02
Drugs
azacitidinefilgrastim
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2013-001639-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001639-38.